Phase 2 Efficacy and Safety Study of Intravenous GPX-150, an Anthracycline Analog, in Patients With Soft Tissue Sarcoma
Phase of Trial: Phase II
Latest Information Update: 22 May 2017
At a glance
- Drugs GPX 150 (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- Sponsors Gem Pharmaceuticals
- 22 Feb 2017 Status changed from active, no longer recruiting to completed.
- 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2016 According to Gem Pharmaceuticals media release, the company announced preliminary results of this trial at the annual meeting of the American Society of Clinical Oncology (ASCO).